Your browser doesn't support javascript.
SARS-CoV-2-specific CD4+ T cell longevity correlates with Th17-like phenotype.
Terahara, Kazutaka; Sato, Takashi; Adachi, Yu; Tonouchi, Keisuke; Onodera, Taishi; Moriyama, Saya; Sun, Lin; Takano, Tomohiro; Nishiyama, Ayae; Kawana-Tachikawa, Ai; Matano, Tetsuro; Matsumura, Takayuki; Shinkai, Masaharu; Isogawa, Masanori; Takahashi, Yoshimasa.
  • Terahara K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Sato T; Tokyo Shinagawa Hospital; Tokyo, 140-8522, Japan.
  • Adachi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Tonouchi K; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Onodera T; Department of Life Science and Medical Bioscience, Waseda University, Tokyo, 162-8480, Japan.
  • Moriyama S; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Sun L; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Takano T; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Nishiyama A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Kawana-Tachikawa A; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Matano T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Matsumura T; AIDS Research Center, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan.
  • Shinkai M; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Isogawa M; Tokyo Shinagawa Hospital; Tokyo, 140-8522, Japan.
  • Takahashi Y; Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
iScience ; 25(9): 104959, 2022 Sep 16.
Article in English | MEDLINE | ID: covidwho-1983265
ABSTRACT
Determinants of memorycell longevity following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain unknown. In addition, phenotypes associated with memorycell longevity, antibody titers, and disease severity are incompletely understood. Here, we longitudinally analyzed SARS-CoV-2-specific T cell and antibody responses of a unique cohort with similar numbers of mild, moderate, and severe coronavirus disease 2019 cases. The half-lives of CD4+ and CD8+ T cells were longer than those of antibody titers and showed no clear correlation with disease severity. When CD4+ T cells were divided into Th1-, Th2-, Th17-, and Tfh-like subsets, the Th17-like subset showed a longer half-life than other subsets, indicating that Th17-like cells are most closely correlated with T cell longevity. In contrast, Th2- and Tfh-like T cells were more closely correlated with antibody titers than other subsets. These results suggest that distinct CD4+ T cell subsets are associated with longevity and antibody responses.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.104959

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Observational study / Prognostic study Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.104959